---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-23-000006"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2023-02-15T23:59:59+00:00"
generated_at: "2026-06-19T11:47:45.580759+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q4 revenue up 9% to $156.2M; FY net loss triples to $166M, guides FY23 rev $580-600M

## Summary
- Q4 2022 revenue $156.2M (+9% YoY); FY 2022 revenue $516.4M (+5% YoY).
- Gross margin fell to 76% in Q4 (from 81%) and 77% for FY (from 85%) due to product mix.
- Operating loss widened to $23.1M in Q4 and $167.9M for FY, driven by higher stock-based compensation.
- Net loss for FY 2022 was $166.0M vs $58.2M in 2021; cash + securities $430M.
- FY 2023 revenue guidance $580M-$600M (12-16% growth); began shipping Xenium in situ platform.

## SEC filing metadata
- accession: 0001770787-23-000006
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2023-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/0001770787-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/txg-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-23-000006
- JSON: https://secwatch.observer/filing/0001770787-23-000006.json
- Plain text: https://secwatch.observer/filing/0001770787-23-000006.txt

## Key facts
- Earnings Releases
  10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $156.2 million for the fourth quarter and $516.4 million for the full year, net income Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022. Guidance initiated.
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: $156.2 million for the fourth quarter and $516.4 million for the full year
  - Net income: Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022
  - Guidance: initiated
  - Result: reported results
  source text: Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023. Recent Highlights • Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022, representing 9% and 5% increases over the corresponding periods of 2021. • Increased cumulative instruments
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770787/000177078723000006/0001770787-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.